SEUNG LEE: Open Payments
NPI 1770693996 · ENGLEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 101 payments from 16 companies in 2025. Trend: 2023 $1,998 · 2024 $2,257 · 2025 $1,636
Food & beverage: $1,636
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $355 |
| Otsuka America Pharmaceutical, Inc. | 20 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $128 |
| Neos Therapeutics, LP | 8 | $126 |
| Vanda Pharmaceuticals Inc. | 7 | $123 |
| Neurocrine BioSciences, Inc. | 7 | $119 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $48 |
| Alkermes, Inc. | 2 | $39 |
Products named: VRAYLAR, CAPLYTA, REXULTI, TRINTELLIX, INGREZZA, HETLIOZ, ABILIFY MAINTENA, Adzenys XR-ODT.
Industry payments across NJ — which companies pay providers there.
